Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Lucozade Energy Original oral solution
191300000BMCZA0
|
Proprietary compound preparation BNF 1913000 | Other cordial/soft drink preparations | Other Drugs and Preparations | No data available |
|
Ludiomil 10mg tablets
0403010S0BBAAAA
|
Ludiomil | Maprotiline hydrochloride | Central Nervous System | No data available |
|
Ludiomil 25mg tablets
0403010S0BBABAB
|
Ludiomil | Maprotiline hydrochloride | Central Nervous System | No data available |
|
Ludiomil 50mg tablets
0403010S0BBACAE
|
Ludiomil | Maprotiline hydrochloride | Central Nervous System | No data available |
|
Ludiomil 75mg tablets
0403010S0BBADAD
|
Ludiomil | Maprotiline hydrochloride | Central Nervous System | No data available |
|
Lumacaftor 100mg / Ivacaftor 125mg granules sachets
0307000T0AAACAC
|
Lumacaftor/ivacaftor | Lumacaftor/ivacaftor | Respiratory System | No data available |
|
Lumacaftor 100mg / Ivacaftor 125mg tablets
0307000T0AAABAB
|
Lumacaftor/ivacaftor | Lumacaftor/ivacaftor | Respiratory System | No data available |
|
Lumacaftor 150mg / Ivacaftor 188mg granules sachets
0307000T0AAADAD
|
Lumacaftor/ivacaftor | Lumacaftor/ivacaftor | Respiratory System | No data available |
|
Lumacaftor 200mg / Ivacaftor 125mg tablets
0307000T0AAAAAA
|
Lumacaftor/ivacaftor | Lumacaftor/ivacaftor | Respiratory System | No data available |
|
Lumecare eyelid wipes
110801000BLATAB
|
Proprietary compound preparation BNF 1108010 | Other eye tear/lubricant/astringent preparations | Eye | No data available |
|
Lumecare Sodium Hyaluronate 0.15% eye drops
21300000118
|
Lumecare Sodium Hyaluronate 0.15% eye drops | Eye Products | Appliances | No data available |
|
Lumiracoxib 100mg tablets
1001010ANAAAAAA
|
Lumiracoxib | Lumiracoxib | Musculoskeletal and Joint Diseases | No data available |
|
Lumiracoxib 400mg tablets
1001010ANAAABAB
|
Lumiracoxib | Lumiracoxib | Musculoskeletal and Joint Diseases | No data available |
|
LumiraDx INR Test testing strips
0208020W0BFAAA0
|
LumiraDx (Reagent) | INR blood testing reagents | Cardiovascular System | No data available |
|
Lunivia 1mg tablets
0401010AEBBAAAA
|
Lunivia | Eszopiclone | Central Nervous System | No data available |
|
Lunivia 2mg tablets
0401010AEBBABAB
|
Lunivia | Eszopiclone | Central Nervous System | No data available |
|
Lunivia 3mg tablets
0401010AEBBACAC
|
Lunivia | Eszopiclone | Central Nervous System | No data available |
|
Lunox Max Strength Sleep Aid 50mg tablets
0304010N0BUABAP
|
Lunox Sleep Aid | Diphenhydramine hydrochloride | Respiratory System | No data available |
|
Lunox Sleep Aid 25mg tablets
0304010N0BUAAAG
|
Lunox Sleep Aid | Diphenhydramine hydrochloride | Respiratory System | No data available |
|
Lupaxis 100mg prolonged-release tablets
0407020AGBEABAD
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lupaxis 150mg prolonged-release tablets
0407020AGBEACAE
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lupaxis 200mg prolonged-release tablets
0407020AGBEADAF
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lupaxis 250mg prolonged-release tablets
0407020AGBEAEAG
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lupaxis 50mg prolonged-release tablets
0407020AGBEAAAC
|
Lupaxis | Tapentadol | Central Nervous System | No data available |
|
Lusama 20micrograms/80microlitres dose inj 2.4ml pf pens
0606010U0BGAAAC
|
Lusama | Teriparatide | Endocrine System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.